No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach

Breast cancer (BC) is globally the most frequent cancer in women. Adherence to endocrine therapy (ET) in hormone-receptor-positive BC patients is active and voluntary for the first five years after diagnosis. This study examines the impact of adherence to ET on 10-year excess mortality (EM) in patie...

Descripción completa

Detalles Bibliográficos
Autores: Clèries, Ramon, Buxó Pujolràs, Maria, Vilardell, Mireia, Ameijide, Alberto, Martínez, José Miguel, Font, Rebeca, Marcos-Gragera, Rafael, Puigdemont, Montserrat, Viñas, Gemma, Carulla, Marià, Espinàs, Josep Alfons, Galceran, Jaume, Izquierdo i Font, Àngel Xavier, Borràs Andrés, Josep Maria
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10256/21760
Acceso en línea:http://hdl.handle.net/10256/21760
Access Level:acceso abierto
Palabra clave:Mama -- Càncer -- Tractament
Breast -- Cancer -- Treatment
Mama -- Càncer -- Hormonoteràpia
Breast -- Cancer -- Hormone therapy
Modelització gràfica (Estadística)
Graphical modeling (Statistics)
Mama -- Càncer -- Mortalitat
Breast -- Cancer -- Mortality
Descripción
Sumario:Breast cancer (BC) is globally the most frequent cancer in women. Adherence to endocrine therapy (ET) in hormone-receptor-positive BC patients is active and voluntary for the first five years after diagnosis. This study examines the impact of adherence to ET on 10-year excess mortality (EM) in patients diagnosed with Stages I to III BC (N = 2297). Since sample size is an issue for estimating age-and stage-specific survival indicators, we developed a method, ComSynSurData, for generating a large synthetic dataset (SynD) through probabilistic graphical modeling of the original cohort. We derived population-based survival indicators using a Bayesian relative survival model fitted to the SynD. Our modeling showed that hormone-receptor-positive BC patients diagnosed beyond 49 years of age at Stage I or beyond 59 years at Stage II do not have 10-year EM if they follow the prescribed ET regimen. This result calls for developing interventions to promote adherence to ET in patients with hormone receptor-positive BC and in turn improving cancer survival. The presented methodology here demonstrates the potential use of probabilistic graphical modeling for generating reliable synthetic datasets for validating population-based survival indicators when sample size is an issue

Similares en LA Referencia